| BD2404Q |
| MBD Market and Business Development Report : Pharmaceutical Products: July 2004 |
|
|
CLICK
TO BUY |
Report Scope
This UK pharmaceutical market research report analyses the industry, covering prescription medicines, and over the counter products. Market trends are fully detailed, including appraisal of demographic factors, expenditure trends, generic activity and outsourcing.LIST OF CONTENTS
| 1. EXECUTIVE SUMMARY |
| 2. INTRODUCTION |
| 2.1 Definitions |
| 2.2 Abbreviations |
| 2.3 Market Positioning |
| 2.4 UK Economy |
| 2.5 Market Factors |
| 3. MARKET SIZE AND TRENDS |
| 3.1 Chapter Summary |
| 3.2 Market Size |
| 3.3 Market Segmentation |
| 3.3.1 Prescription Medicines |
| 3.3.2 OTC Medicines |
| 3.4 Market Trends |
| 3.4.1 Demographics |
| 3.4.2 Expenditure |
| 3.4.3 Generics |
| 3.4.4 Outsourcing |
| 3.4.5 Parallel Trade |
| 3.4.6 Herbal Medicines |
| 4. SUPPLY SOURCES |
| 4.1 Chapter Summary |
| 4.2 Production |
| 4.2.1 Overview |
| 4.2.2 Segmentation |
| 4.3 Imports |
| 4.3.1 Overview |
| 4.3.2 Segmentation |
| 4.4 Exports |
| 4.4.1 Overview |
| 4.4.2 Segmentation |
| 4.5 Trade Surplus/Deficit |
| 5. INDUSTRY STRUCTURE |
| 5.1 Chapter Summary |
| 5.2 Industry Development |
| 5.3 Structure by Employment |
| 5.4 Structure by Turnover |
| 5.5 Company Profiles |
| 5.5.1 American Home Products Holdings (UK) |
| 5.5.2 Amersham |
| 5.5.3 AstraZeneca |
| 5.5.4 Bristol-Myers Squibb Pharmaceuticals |
| 5.5.5 Celltech Group |
| 5.5.6 Eli Lilly & Co |
| 5.5.7 GlaxoSmithKline |
| 5.5.8 Johnson & Johnson |
| 5.5.9 Merck |
| 5.5.10 Merial |
| 5.5.11 Novartis UK |
| 5.5.12 Pfizer |
| 5.5.13 Pharmacia |
| 5.5.14 Roche Products |
| 5.5.15 Shire Pharmaceuticals Group |
| 5.5.16 Unichem |
| 6. FORECAST |
| 6.1 Chapter Summary |
| 6.2 Market Size |
| 6.3 Market Segmentation |
| 6.4 Production |
| 6.5 Imports |
| 6.6 Industry |
| 7. FURTHER SOURCES & CONTACTS |
| 7.1 Trade Associations |
| 7.2 Trade Magazines |
| 7.3 Trade Exhibitions |
LIST OF TABLES
| 1: UK Apparent Consumption for Pharmaceutical Products, 1998-2002 |
| 2: UK Market for Pharmaceutical Products, 1998-2002 |
| 3: Segmentation of the UK Market for Pharmaceutical Products, 1998-2002 |
| 4: Segmentation of the UK Market for Pharmaceutical Products, 1998-2002 |
| 5: Number of Prescription Items Dispensed in the UK Market, by Country, 1998-2002 |
| 6: Prescription Items Dispensed in the UK Market, by Disease, 2002 |
| 7: UK Market for OTC Pharmaceutical Products and Top Branded Sellers, by |
| Therapeutic Category, 2002 |
| 8: UK Population, by Age Group, 1981-2021 |
| 9: NHS Expenditure on Medicines in the UK, 1998-2002 |
| 10: UK Production of Pharmaceutical Products, 1998-2002 |
| 11: Segmentation of the UK Production of Pharmaceutical Products, by Type, 1998-2002 |
| 12: UK Imports of Pharmaceutical Products, 1998-2002 |
| 13: Segmentation of UK Imports of Pharmaceutical Products, by Type, 1998-2002 |
| 14: UK Exports of Pharmaceutical Products, 1998-2002 |
| 15: Segmentation of UK Exports of Pharmaceutical Products, by Type, 1998-2002 |
| 16: Analysis of the Changes in the Structure of the Basic Pharmaceuticals Manufacturing Industry, 1998-2002 |
| 17: Analysis of the Changes in the Structure of the Pharmaceutical Preparations |
| Manufacturing Industry, 1998-2002 |
| 18: Analysis of the Employment Structure of the Basic Pharmaceuticals Manufacturing |
| Industry, 2003 |
| 19: Analysis of the Employment Structure of the Pharmaceutical Preparations |
| Manufacturing Industry, 2003 |
| 20: Analysis of the Financial Structure of the Basic Pharmaceuticals Manufacturing |
| Sector, 2002 and 2003 |
| 21: Analysis of the Financial Structure of the Pharmaceutical Preparations |
| Manufacturing Sector, 2002 and 2003 |
| 22: Financial Analysis of American Home Products Holdings (UK), 1997-2001 |
| 23: Key Financial Ratios for American Home Products Holdings (UK), 2000-2001 |
| 24: Financial Analysis of Amersham, 1997-2001 |
| 25: Key Financial Ratios for Amersham, 2000-2001 |
| 27: Key Financial Ratios for AstraZeneca, 2001-2002 |
| 28: Financial Analysis of Bristol-Myers Squibb Pharmaceuticals, 1997-2001 |
| 29: Key Financial Ratios for Bristol-Myers Squibb Pharmaceuticals, 2000-2001 |
| 30: Financial Analysis of Celltech Group, 1997-2001 |
| 31: Key Financial Ratios for Celltech Group, 2000-2001 |
| 32: Financial Analysis of Eli Lilly & Company, 1997-2001 |
| 33: Key Financial Ratios for Eli Lilly & Co, 2000-2001 |
| 34: Financial Analysis of GlaxoSmithKline, 2000-2002 |
| 35: Key Financial Ratios for GlaxoSmithKline, 2001-2002 |
| 36: Financial Analysis of Johnson & Johnson, 1997-2001 |
| 37: Key Financial Ratios for Johnson & Johnson, 2000-2001 |
| 38: Financial Analysis of Merck, 1997-2001 |
| 39: Analysis of Merck Turnover, by Activity, 1997-2001 |
| 40: Key Financial Ratios for Merck, 2000-2001 |
| 41: Financial Analysis of Merial, 1997-2001 |
| 42: Key Financial Ratios for Merial, 2000-2001 |
| 43: Financial Analysis of Novartis UK, 1997-2001 |
| 44: Key Financial Ratios for Novartis UK, 2000-2001 |
| 45: Financial Analysis of Pfizer, 1997-2001 |
| 46: Key Financial Ratios for Pfizer, 2000-2001 47: Financial Analysis of Pharmacia, 1998-2002 |
| 48: Key Financial Ratios for Pharmacia, 2001-2002 |
| 49: Financial Analysis of Roche Products, 1997-2001 |
| 50: Key Financial Ratios for Roche Products, 2000-2001 |
| 51: Financial Analysis of Shire Pharmaceuticals Group, 1997-2001 |
| 52: Key Financial Ratios for Shire Pharmaceuticals Group, 2000-2001 |
| 53: Financial Analysis of Unichem, 1999-2001 |
| 54: Key Financial Ratios for Unichem, 2000-2001 |
| 55: Forecast UK Market for Pharmaceutical Products, 2003-2007 |
| 56: Forecast Segmentation of the UK Market for Pharmaceutical Products, 2003-2007 |
| 57: Forecast UK Production of Pharmaceutical Products, 2003-2007 |
| 58: Forecast UK Imports of Pharmaceutical Products, 2003-2007 |
EXECUTIVE SUMMARY
awaiting details from publishers
Text © 2004 MBD
| Can't find what you
need? Try our "Research on Request" market report service and define your own report research! Fixed prices - £150, £450 and £1,250 - and fixed delivery of 4, 5 and 14 days |
| Click here for full details |
Ariadne - working together with our customers
to enhance productivity and increase knowledge
© 2004
www.the-list.co.uk Ariadne
Last updated by Amanda Porteous 2004